The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
Open Access
Abstract
Objectives The aim of the present study was to estimate the cost-effectiveness of the polypill in the primary prevention of cardiovascular disease. Design A health economic modelling study. Setting Primary healthcare in the Netherlands. Participants Simulated individuals from the general Dutch population, aged 45–75 years. Interventions Opportunistic screening followed by prescription of the polypill to eligible individuals. Eligibility was defined as having a minimum 10-year risk of cardiovascular death as assessed with the Systematic Coronary Risk Evaluation function of alternatively 5%, 7.5% or 10%. Different versions of the polypill were considered, depending on composition: (1) the Indian polycap, with three different types of blood pressure-lowering drugs, a statin and aspirin; (2) as (1) but without aspirin and (3) as (2) but with a double statin dose. In addition, a scenario of (targeted) separate antihypertensive and/or statin medication was simulated. Primary outcome measures Cases of acute myocardial infarction or stroke prevented, quality-adjusted life years (QALYs) gained and the costs per QALY gained. All interventions were compared with usual care. Results All scenarios were cost-effective with an incremental cost-effectiveness ratio between €7900 and 12 300 per QALY compared with usual care. Most health gains were achieved with the polypill without aspirin and containing a double dose of statins. With a 10-year risk of 7.5% as the threshold, this pill would prevent approximately 3.5% of all cardiovascular events. Conclusions Opportunistic screening based on global cardiovascular risk assessment followed by polypill prescription to those with increased risk offers a cost-effective strategy. Most health gain is achieved by the polypill without aspirin and a double statin dose.Keywords
This publication has 46 references indexed in Scilit:
- Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and AgePLOS ONE, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Problems of Nonadherence in Cardiology and Proposals to Improve OutcomesThe American Journal of Cardiology, 2010
- Evaluation of cardiovascular risk predicted by different SCORE equations: The Netherlands as an exampleEuropean Journal of Preventive Cardiology, 2010
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trialsBMJ, 2008
- Impact of Fixed-Dose Combination Drugs on Adherence to Prescription MedicationsJournal of General Internal Medicine, 2008
- Predictors of Adherence to Concomitant Antihypertensive and Lipid-Lowering Medications in Older AdultsDrugs & Aging, 2008
- Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)European Journal of Preventive Cardiology, 2007
- Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agentsAmerican Journal of Health-System Pharmacy, 2007